Publication | Closed Access

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

Cancer ImmunosurveillanceMedicineTrail Receptor-1ImmunologyImmune Checkpoint InhibitorCancer TreatmentPhase 2OncologyRadiation OncologyLung Cancer